Please assess the completion status of the following clinical trial:

Trial Title: Bronchial Hyper-responsiveness in Reflux Cough

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Positive methacholine challenge test PC20 less than 4mg/ml (Can be previously documented in patients notes within last 4weeks)~* Written informed consent~* Patients with a history of chronic cough (at least 3 months duration), and associated symptoms of gastro-oesophageal reflux~* Male and female subjects of at least 18 yrs of age~* Subjects able to perform satisfactory FEV1 manoeuvres~* Subjects able to understand the study and co-operate with the study procedures~* Subjects who consent to their general practitioner (GP) being informed of their study participation~Exclusion Criteria:~* has had a heart attack in the last three months~* suffers from angina, hypertension or ischaemic heart disease~* has epilepsy for which he/she is taking medication~* FEV1\< 60% predicted~* FEV1\<1.6L~* Female subjects who are pregnant, or lactating, or who are of child bearing potential but are not using contraceptive measures~* Suffering from any concomitant disease which may interfere with study procedures or evaluation.~* A lower respiratory tract infection 4 weeks prior to entry on to study~* Participation in another study (use of investigational product) within 30 days preceding entry on to study.~* Alcohol or drug abuse~* Use of opiates to treat cough 1 week prior to enrollment~* Subjects who are taking Angiotensin Converting Enzymes (ACE) inhibitors.~* Subjects who have significant pathology on most recent chest X-Ray.~* Inability to understand the procedures and the implications of a challenge test~* Patients already taking or have taken in last 4 weeks PPI and H2 receptor antagonist (full acid suppression treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- omeprazole and ranitidine (Type: OTHER): 20 mg oralomeprazole oral tablet twice daily and ranitidine 300 mg oral tablet once daily nocte

Based on this trial design, predict the completion outcome and termination type (if applicable).